The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Cyclin E in normal and neoplastic cell cycles
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Inhibitors of mammalian G1 cyclin-dependent kinases.
Sherr, C. J., & Roberts, J. M. (1995) · Genes & Development · doi:10.1101/gad.9.10.1149 · Cited by 3,243
G1 phase progression: Cycling on cue
Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90540-1 · Cited by 2,674
The regulation of E2F by pRB-family proteins.
Dyson, N. (1998) · Genes & Development · doi:10.1101/gad.12.15.2245 · Cited by 2,317
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690 · cited 1×
“Cyclin E is a component of the retinoblastoma (Rb) pathway, in which progressive phosphorylation of Rb by cyclin D-Cdk4/6 and cyclin E-Cdk2 releases E2F and promotes S-phase entry (reviewed in (Bartek et al., 1997; Sherr and McCormick, 2002).”
BackgroundSKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27
Carrano, A. C., Eytan, E., Hershko, A., & Pagano, M. (1999) · Nature Cell Biology · doi:10.1038/12013 · Cited by 1,543
SCF and Cullin/RING H2-Based Ubiquitin Ligases
Deshaies, R. J. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.435 · Cited by 1,242
Skowyra, D., Craig, K. L., Tyers, M., Elledge, S. J., & Harper, J. W. (1997) · Cell · doi:10.1016/s0092-8674(00)80403-1 · Cited by 1,224
Human Cyclin E, a Nuclear Protein Essential for the G1-to-S Phase Transition
Ohtsubo, M., Theodoras, A. M., Schumacher, J., Roberts, J. M., & Pagano, M. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.5.2612 · Cited by 1,148
Distinct Roles for Cyclin-Dependent Kinases in Cell Cycle Control
van den Heuvel, S., & Harlow, E. (1993) · Science · doi:10.1126/science.8266103 · Cited by 1,092
Cited by
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986
Mammalian cyclin-dependent kinases
Malumbres, M., & Barbacid, M. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.09.005 · Cited by 1,295
Welcker, M., & Clurman, B. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2290 · Cited by 1,084
Self-citationNucleotide deficiency promotes genomic instability in early stages of cancer development
Bester, A. C., Roniger, M., Oren, Y. S., Im, M. M., Sarni, D., Chaoat, M., Bensimon, A., Zamir, G., Shewach, D. S., & Kerem, B. (2011) · Cell · doi:10.1016/j.cell.2011.03.044 · Cited by 858
Mutual exclusivity analysis identifies oncogenic network modules
Ciriello, G., Cerami, E., Sander, C., & Schultz, N. (2012) · Genome Research · doi:10.1101/gr.125567.111 · Cited by 675
The Salvador–Warts–Hippo pathway — an emerging tumour-suppressor network
Harvey, K., & Tapon, N. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2070 · Cited by 628
Targeting cell-cycle machinery in cancer
Suski, J. M., Braun, M., Strmiska, V., & Sicinski, P. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.010 · Cited by 564
Evaluation of the use of therapeutic peptides for cancer treatment
Marqus, S., Pirogova, E., & Piva, T. J. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0328-x · Cited by 512
Hao, B., Oehlmann, S., Sowa, M. E., Harper, J. W., & Pavletich, N. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.022 · Cited by 460
The cell cycle in stem cell proliferation, pluripotency and differentiation
Liu, L., Michowski, W., Kolodziejczyk, A., & Sicinski, P. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0384-4 · Cited by 414
Posttranscriptional regulation of cancer traits by HuR
Abdelmohsen, K., & Gorospe, M. (2010) · WIREs RNA · doi:10.1002/wrna.4 · Cited by 412
Yang, R., Xing, L., Zheng, X., Sun, Y., Wang, X., & Chen, J. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0933-7 · Cited by 332
RetractedCyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 304
Etemadmoghadam, D., deFazio, A., Beroukhim, R., Mermel, C., George, J., Getz, G., Tothill, R., Okamoto, A., Raeder, M. B., AOCS Study Group, et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1564 · Cited by 302
Senescence from G2 arrest, revisited
Gire, V., & Dulić, V. (2015) · Cell Cycle · doi:10.1080/15384101.2014.1000134 · Cited by 300
Jones, R. M., Mortusewicz, O., Afzal, I., Lorvellec, M., García, P., Helleday, T., & Petermann, E. (2013) · Oncogene · doi:10.1038/onc.2012.387 · Cited by 295
Cell cycle regulation by long non-coding RNAs
Kitagawa, M., Kitagawa, K., Kotake, Y., Niida, H., & Ohhata, T. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1423-0 · Cited by 278
Cyclin E/CDK2: DNA Replication, Replication Stress and Genomic Instability
Fagundes, R., & Teixeira, L. K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.774845 · Cited by 276
Foster, D. A., Yellen, P., Xu, L., & Saqcena, M. (2010) · Genes & Cancer · doi:10.1177/1947601910392989 · Cited by 275
DNA Damage Response Genes and the Development of Cancer Metastasis
Broustas, C. G., & Lieberman, H. B. (2014) · Radiation Research · doi:10.1667/rr13515.1 · Cited by 275
Kinase-independent function of cyclin E
Geng, Y., Lee, Y.-M., Welcker, M., Swanger, J., Zagozdzon, A., Winer, J. D., Roberts, J. M., Kaldis, P., Clurman, B. E., & Sicinski, P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.11.029 · Cited by 187
Self-citationMafi, A., Rahmati, A., Babaei Aghdam, Z., Salami, R., Salami, M., Vakili, O., & Aghadavod, E. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00354-4 · Cited by 56
Sicinska, E., Lee, Y.-M., Gits, J., Shigematsu, H., Yu, Q., Rebel, V. I., Geng, Y., Marshall, C. J., Akashi, K., Dorfman, D. M., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00800-06 · Cited by 45
Cyclers’ kinases in cell division: from molecules to cancer therapy
Milletti, G., Colicchia, V., & Cecconi, F. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01196-z · Cited by 39
Davis, R. J., Swanger, J., Hughes, B. T., & Clurman, B. E. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00657-16 · Cited by 15
“Cells must tightly regulate cyclin E-CDK2 activity, and this is accomplished through a variety of mechanisms, including E2F-dependent cyclin E transcription, binding of CDK inhibitor proteins (p27Kip1 and p21Cip1), activating and inhibitory phosphorylation of CDK2, and cyclin E degradation by the ubiquitin-proteasome…”
Self-citationResistance Mechanisms to Cyclin-Dependent Kinase Inhibitors
Wiedemeyer, W. R. (2018) · Resistance to Targeted Anti-Cancer Therapeutics · doi:10.1007/978-3-319-67932-7_8 · Cited by 7
Metadata
- Authors
- Hwang, H. C., & Clurman, B. E.
- Venue
- Oncogene
- Published
- 2005-04-18
- Volume
- 24
- Issue
- 17
- Pages
- 2776-2786
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2091327303
- Cited by
- 514
- References
- 115
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.